论文部分内容阅读
Objective: To compare the effects of continuous combined 17β - estradiol (E2) plus norethisterone (acetate) [NET(A)] therapy by either intranasal or oral administration on the lipid profile in postmenopausal women.Design: Randomized, double- blind, multicenter trial.Setting: Gynecologic outpatient department.Patient(s): Two- hundred thirty- three healthy postmenopausal women.Intervention(s): Women received continuous combined hormone therapy, either intranasal E2/NET (175 μ g/275 μ g) as a spray (n = 117) or oral E2/NETA (1 mg/0.5 mg) as a capsule (n = 116), for 1 year.Main Outcome Measure(s): Fasting plasma concentrations of lipids and (apo)lipoproteins; and atherogenic indices at baseline and after 12, 24, and 52 weeks of treatment.Result(s): We found a significant (P < .001) decrease from baseline in both treatment groups in total, low- density lipoprotein- (LDL), high- density lipoprotein- (HDL), and HDL 2- cholesterol, in triglycerides, apolipoprotein B (apoB), and lipoprotein(a). Lvels of HDL 3- cholesterol and apolipoprotein A1 (apoA1) were transiently decreased in the intranasal group.In the oral group, compared with the intranasal group, the decrease was larger for ratio total and LDL- cholesterol and lipoprotein(a) and smaller for triglycerides and apoA1.In the oral group, the ratios total/HDL cholesterol and LDL/HDL cholesterol were lowered, and the ratio apoB/LDL was increased, more than in the intranasal group.Conclusion(s): Both intranasal and oral E2/NET(A) therapy improved the lipid profile of healthy postmenopausal women, with some effects being more pronounced after oral administration.
Objective: To compare the effects of continuously combined 17β-estradiol (E2) plus norethisterone (acetate) [NET (A)] therapy by either intranasal or oral administration on the lipid profile in postmenopausal women. Design: Randomized, double-blind, multicenter Trial.Setting: Gynecologic outpatient department. Patient (s): Two-hundred thirty-three healthy postmenopausal women. Intervention (s): Women received continuous combined hormone therapy, either intranasal E2 / NET (175 μ g / 275 μ g) as Fasting plasma concentrations of lipids and (apo) lipoproteins; a spray (n = 117) or oral E2 / NETA Results (a): We found a significant (P <.001) decrease from baseline in both treatment groups in total, low-density lipoprotein- (LDL) and atherogenic indices at baseline and after 12, , high density lipoprotein- (HDL), and HDL 2-cholesterol, in triglycerides, apolipoprotein B (apoB), and lipoprotein a). Lvels of HDL 3-cholesterol and apolipoprotein A1 (apoAl) were transiently decreased in the intranasal group. the oral group, compared with the intranasal group, the decrease was larger for ratio total and LDL- cholesterol and lipoprotein (a) and smaller for triglycerides and apoAl. In the oral group, the ratios total / HDL cholesterol and LDL / HDL cholesterol were lowered, and the ratio apoB / LDL was increased, more than in the intranasal group. Conflusion (s): Both intranasal and oral E2 / NET (A) therapy improved the lipid profile of healthy postmenopausal women, with some effects being more pronounced after oral administration.